Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the NICE appraisal of Kuvan will consider the increased prevalence of neuropsychiatric comorbidities in adults with phenylketonuria.

In developing its recommendations on Kuvan, the National Institute for Health and Care Excellence (NICE) will consider all the health-related costs and benefits associated with the treatment in accordance with its published methods and processes and the scope for the appraisal that has been developed in consultation with stakeholders; potentially including any costs from National Health Service funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.